Abstract
Introduction
Molecular targeted cancer therapies are the biggest and fastest growing class
of cancer drugs in terms of sales. As growth of revenues from cytotoxic
therapies and antihormonal therapies has slowed and many key brands in these
classes face imminent patent expiries, it is unsurprising that the major
oncology companies have shifted their focus towards the molecular targeted
cancer therapies market.
Scope of this research
- Forecast sales of every marketed molecular targeted cancer therapy in each
of the seven major markets over the period 2008 to 2018
- Analysis and segmentation of the market at various levels including drug
class, country, brand and company
- Comprehensive brand profiles and analysis for the key brands, including
approval dates, patent expiries and all key events likely to impact sales
- Snapshot of the molecular targeted cancer therapies market in the rest of
the world
Research and analysis highlights
Total sales of marketed molecular targeted cancer therapies in the seven major
pharmaceutical markets will grow at a CAGR of 9.8% from $17.5 billion in 2008
to $44.7 billion in 2018. Drivers of growth will include the continuing
adoption of molecular targeted cancer therapies in currently approved
indications and approvals in new indications.
Avastin (bevacizumab; Roche/Chugai) was the top-selling molecular targeted
cancer therapy brand in 2008, and will remain the leading brand in 2018.
Avastin will achieve this growth through indication expansion across a number
of new tumor types and increasing uptake in new territories.
With a dominant presence in three of the four highest incidence solid tumors
and the highest incidence hematological malignancy, Roche has established a
stranglehold over the molecular targeted cancer therapies market. This will
continue through to 2018, driven mainly by the strong performance of the
company' s monoclonal antibody franchise.
Key reasons to purchase this research
- Quantify the performance of each of the marketed molecular targeted cancer
therapies in the seven major markets over the period 2008 to 2018
- Assess the changing key opportunities and threats both for currently
marketed and pipeline targeted therapy cancer brands
- Identify the leading brands in this market over the next 10 years and
understand the key factors driving their success
| 
View Cart
